Page 50 - TD-3-1

Tumor Discovery Energy metabolism in bladder cancer

2009;56:430-442. mitochondrial function and metabolic reprogramming
during tumor progression in a cell model of skin
doi: 10.1016/j.eururo.2009.06.028
carcinogenesis. Biochimie. 2013;95:1171-1176.
8. Cote RJ, Chatterjee SJ. Molecular determinants of outcome
in bladder cancer. Cancer J Sci Am. 1999;5:2-15. doi: 10.1016/j.biochi.2013.01.001
20. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The world
9. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter
VE. The 2016 WHO classification of tumours of the urinary health organization/International society of urological
system and male genital organs-part B: Prostate and bladder pathology consensus classification of urothelial (transitional
tumours. Eur Urol. 2016;70:106-119. cell) neoplasms of the urinary bladder. Bladder Consensus
Conference Committee. Am J Surg Pathol. 1998;22:1435-1448.
doi: 10.1016/j.eururo.2016.02.028
doi: 10.1097/00000478-199812000-00001
10. Kunju LP, You L, Zhang Y, Daignault S, Montie JE,
Lee CT. Lymphovascular invasion of urothelial cancer in 21. Fávaro WJ, Alonso JC, De Souza BR, et al. New synthetic
matched transurethral bladder tumor resection and radical nano-immunotherapy (OncoTherad®) for non-muscle
cystectomy specimens. J Urol. 2008;180:1928-1932. invasive bladder cancer: Its synthesis, characterization and
anticancer property. Tissue Cell. 2023;80:101988.
doi: 10.1016/j.juro.2008.07.056
doi: 10.1016/j.tice.2022.101988
11. Semeniuk-Wojtaś A, Poddębniak-Strama K, e, et al. Tumour
microenvironment as a predictive factor for immunotherapy 22. Reis IB, Tibo LH, Socca EA, De Souza BR, Durán N, Fávaro
in non-muscle-invasive bladder cancer. Cancer Immunol WJ. OncoTherad® (MRB-CFI-1) nano-immunotherapy
Immunother. 2023;72(7):1971-1989. reduced tumoral progression in non-muscle invasive
bladder cancer through activation of Toll-like signaling
doi: 10.1007/s00262-023-03376-9 pathway. Tissue Cell. 2022;76:101762.
12. Domblides C, Lartigue L, Faustin B. Control of the doi: 10.1016/j.tice.2022.101762
antitumor immune response by cancer metabolism. Cells.
2019;8(2):104. 23. Cuezva JM, Chen G, Alonso AM, et al. The bioenergetic
signature of lung adenocarcinomas is a molecular marker
doi: 10.3390/cells8020104 of cancer diagnosis and prognosis. Carcinogenesis.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: The next 2004;25:1157-1163.
generation. Cell. 2011;144:646-674. doi: 10.1093/carcin/bgh113
doi: 10.1016/j.cell.2011.02.013 24. O’Donnell MA. Practical applications of intravesical
14. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. chemotherapy and immunotherapy in high-risk patients
The biology of cancer: Metabolic reprogramming fuels cell with superficial bladder cancer. Urol Clin North Am.
growth and proliferation. Cell Metab. 2008;7:11-20. 2005;32:121-131.
doi: 10.1016/j.cmet.2007.10.002 doi: 10.1016/j.ucl.2005.01.003

15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding 25. Lobo N, Martini A, Kamat AM. Evolution of immunotherapy
the Warburg effect: The metabolic requirements of cell in the treatment of non-muscle-invasive bladder cancer.
proliferation. Science. 2009;324:1029-1033. Expert Rev Anticancer Ther. 2022;22:361-370.
doi: 10.1126/science.1160809 doi: 10.1080/14737140.2022.2046466
16. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell 26. Böhle A, Brandau S. Immune mechanisms in bacillus
metabolism. Nat Rev Cancer. 2011;11:85-95. Calmette-Guerin immunotherapy for superficial bladder
cancer. J Urol. 2003;170:964-969.
doi: 10.1038/nrc2981
doi: 10.1097/01.ju.0000073852.24341.4a
17. Cuezva JM, Krajewska M, De Heredia ML, et al. The
bioenergetic signature of cancer: A marker of tumor 27. Wood D. Tumors of the bladder. In: Wein AJ, Kavoussi LR,
progression. Cancer Res. 2002;62:6674-6681. Partin AW, Peters CA, editors. Campbell-Walsh Urology.
11 ed. Philadelphia, PA: Elsevier; 2016.
th
18. Isidoro A, Martínez M, Fernández PL, et al. Alteration of
the bioenergetic phenotype of mitochondria is a hallmark 28. Lim HY, Ho QS, Low J, Choolani M, Wong KP. Respiratory
of breast, gastric, lung and oesophageal cancer. Biochem J. competent mitochondria in human ovarian and peritoneal
2004;378:17-20. cancer. Mitochondrion. 2011;11:437-443.
doi: 10.1042/BJ20031541 doi: 10.1016/j.mito.2010.12.015
19. Vallejo CG, Cruz-Bermudez A, Clemente P, Hernandez- 29. Macheda ML, Rogers S, Best JD. Molecular and cellular
Sierra R, Garesse R, Quintanilla M. Evaluation of regulation of glucose transporter (GLUT) proteins in cancer.

Volume 3 Issue 1 (2024) 14 https://doi.org/10.36922/td.2290